These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29696833)

  • 1. Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
    van Vollenhoven RF; Lee EB; Fallon L; Zwillich SH; Wilkinson B; Chapman D; DeMasi R; Keystone E
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):71-79. PubMed ID: 29696833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
    Strand V; Lee EB; Yazici Y; Dikranian A; Wilkinson B; Takiya L; Zang C; Bananis E; Bergman MJ
    Clin Rheumatol; 2018 Aug; 37(8):2043-2053. PubMed ID: 29656373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
    Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
    Smolen JS; Aletaha D; Gruben D; Zwillich SH; Krishnaswami S; Mebus C
    Arthritis Rheumatol; 2017 Apr; 69(4):728-734. PubMed ID: 27907269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
    Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
    RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
    van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
    Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
    Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
    Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
    Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
    Takeuchi T; Fleischmann R; Iikuni N; Shi H; Soma K; Paulissen J; Hirose T; Smolen JS
    Arthritis Res Ther; 2021 Aug; 23(1):220. PubMed ID: 34429160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.
    Fleischmann R; Haraoui B; Buch MH; Gold D; Sawyerr G; Shi H; Diehl A; Lee K
    Rheumatol Ther; 2023 Apr; 10(2):375-386. PubMed ID: 36534208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
    van der Heijde D; Tanaka Y; Fleischmann R; Keystone E; Kremer J; Zerbini C; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Wyman BT; Gruben D; Benda B; Wallenstein G; Krishnaswami S; Zwillich SH; Bradley JD; Connell CA;
    Arthritis Rheum; 2013 Mar; 65(3):559-70. PubMed ID: 23348607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.
    Strand V; Kavanaugh A; Kivitz AJ; van der Heijde D; Kwok K; Akylbekova E; Soonasra A; Snyder M; Connell C; Bananis E; Smolen JS
    Rheumatol Ther; 2018 Dec; 5(2):341-353. PubMed ID: 29761420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 18. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.